Rahman Mantaka, Tabassum Ashiqa, Sultana Sharmin, Saha Tamal, Nayeem Md Abu Jaher, Jahan Israt, Hasan Imran, Hayat Shoma, Papri Nowshin, Islam Zhahirul
Gut Brain Axis Laboratory, icddr,b, Dhaka, Bangladesh.
Gut Brain Axis Laboratory, icddr,b, Dhaka, Bangladesh
BMJ Open. 2025 Aug 21;15(8):e105955. doi: 10.1136/bmjopen-2025-105955.
Alzheimer's disease (AD) impacts over 55 million individuals worldwide and remains the leading cause of dementia (60-70% of cases). By 2050, South and Southeast Asia are projected to have an older adult population more than double, bearing a major share of Alzheimer's disease burden. This will exert a heavy strain on healthcare systems, particularly in resource-limited countries where support and infrastructure are already stretched. Despite this, no review has yet explored the regional epidemiology and associated risk factors in this context. Thus, this study protocol outlines to synthesise prevailing evidence from these densely populated regions, particularly low- and middle-income nations within South and Southeast Asia.
This review will include studies that reported epidemiological characteristics including prevalence, age of onset, mortality, and risk factors of AD and related dementias comprising in South and Southeast Asian regions. Studies published in any language from inception to date will be extracted from PubMed, Scopus, CINAHL, EMBASE and APA PsycNet, following Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We will also search grey literature sources and screen the reference lists of the articles selected for full-text review to identify additional relevant studies. Observational studies including case-control, cohort, and cross-sectional designs reporting desired outcomes will be included and appraised for quality assessment with the modified Newcastle-Ottawa Scale (mNOS). The included articles will be appraised by two independent reviewers, with a third resolving any conflicts. Pooled estimates of prevalence, age of onset and mortality will be analysed using random effect meta-analysis (REML) model. Associated risk factors, including modifiable and non-modifiable will be narratively synthesised. Forest plots will be used to visualise the findings, and heterogeneity across the included studies will be assessed using the ² and Cochrane's statistics. Potential publication bias will be assessed using a funnel plot along with the Begg's and Egger's tests. Sensitivity and subgroup analyses will also be conducted to assess the robustness of pooled estimates and to explore potential sources of heterogeneity. Statistical analysis will be conducted using Rstudio (v.4.3.2) and GraphPad Prism V.9.0.2.
The systematic review is focused on the analysis of secondary data from published literature; thus, no ethical approval will be needed. The protocol will follow international standard guidelines, findings will be reported in a reputed journal and disseminated through (inter)national conferences, webinars and key stakeholders to inform policy, research and AD management strategies.
CRD 420251047105.
阿尔茨海默病(AD)影响着全球超过5500万人,仍然是痴呆症的主要病因(占病例的60 - 70%)。预计到2050年,南亚和东南亚的老年人口将增加一倍多,承担着阿尔茨海默病负担的主要份额。这将给医疗系统带来沉重压力,尤其是在资源有限的国家,这些国家的支持和基础设施已经捉襟见肘。尽管如此,尚无综述探讨这一背景下的区域流行病学及相关风险因素。因此,本研究方案概述了综合来自这些人口密集地区,特别是南亚和东南亚低收入和中等收入国家的现有证据。
本综述将纳入报告了南亚和东南亚地区AD及相关痴呆症的流行病学特征(包括患病率、发病年龄、死亡率和风险因素)的研究。从创刊至今以任何语言发表的研究将从PubMed、Scopus、CINAHL、EMBASE和APA PsycNet中提取,遵循系统评价和Meta分析的首选报告项目(PRISMA)以及流行病学观察性研究的Meta分析(MOOSE)指南。我们还将搜索灰色文献来源,并筛选选定进行全文审查的文章的参考文献列表,以识别其他相关研究。将纳入包括病例对照、队列和横断面设计并报告预期结果的观察性研究,并用改良的纽卡斯尔 - 渥太华量表(mNOS)进行质量评估。纳入的文章将由两名独立评审员进行评估,如有冲突将由第三名评审员解决。患病率、发病年龄和死亡率的合并估计将使用随机效应Meta分析(REML)模型进行分析。将对相关风险因素,包括可改变和不可改变的风险因素进行叙述性综合。森林图将用于直观呈现研究结果,纳入研究之间的异质性将使用I²和Cochrane's Q统计量进行评估。潜在的发表偏倚将使用漏斗图以及Begg检验和Egger检验进行评估。还将进行敏感性和亚组分析,以评估合并估计的稳健性并探索异质性的潜在来源。统计分析将使用Rstudio(v.4.3.2)和GraphPad Prism V.9.0.2进行。
本系统评价专注于对已发表文献中的二手数据进行分析;因此,无需伦理批准。该方案将遵循国际标准指南,研究结果将在著名期刊上发表,并通过(国际)会议、网络研讨会和关键利益相关者进行传播,以为政策、研究和AD管理策略提供信息。
PROSPERO注册号:CRD 420251047105。